ARS Pharmaceuticals, Inc.
NASDAQ:SPRYBiotechnology
-$0.35 today
- Market cap
- $370.95M
- Beta
- 0.83
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.99
Volume 1.70M
Average 1.67M
SPRY Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ARS Pharmaceuticals, Inc.NASDAQ: SPRY
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin remains negative
Q1 FY2026 selling, general & admin was $72.2M, compared with $0 a year earlier. Trailing-twelve-month selling, general & admin was $261.22M. Over 3 fiscal years it compounded at +131.1% a year.
Context
- Selling, general & admin amounted to 273.1% of revenue in FY2025, up 273.1 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $38.4B (+16584.6%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $72.2M+20.4% QoQ
- Last fiscal yearDec 2025
- $230.12M— YoY
- LTMMar 2026
- $261.22M+825.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +18283.1% | — |
| 1 year | — | +16584.6% | — |
| 3-year CAGR | +131.1% | +598.1% | +467.1 pp |
| 5-year CAGR | +245.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 230.12M USD
- Year-over-year change
- —
- 4-year CAGR
- +164.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 230.12M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 47.28M | +153.5% |
| FY2022 | 2022-12-31 | 18.66M | +298.0% |
| FY2021 | 2021-12-31 | 4.69M | — |
Selling, General & Admin vs competitors
How SPRY compares with its peers on the latest reported figures
- SPRY's LTM Mar 2026 selling, general & admin of $261.22M is the highest of the 4 companies compared; the peer median is $173.21M.
- Its year-over-year change of +825.5% is the highest of 4, against a peer median of +22.5%.
- Selling, general & admin amounts to 263.9% of revenue for SPRY, versus a peer median of 60.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $261.22M | +825.5% | +131.1% | 263.9% |
| LTM Mar 2026 | $191.5M | +13.2% | +9.8% | 60.8% | |
| LTM Mar 2026 | $173.21M | +78.5% | +16.4% | 48.0% | |
| LTM Mar 2026 | $71.75M | +22.5% | +14.7% | 142.7% | |
| Peer median (excluding SPRY) | $173.21M | +22.5% | +14.7% | 60.8% | |
Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.51M | 1.32M | 30K | 89.15M | 84.28M |
| Cost of Revenue | 213K | 17.12M | 0 | 20.56M | 20.42M |
| Gross Profit | 5.29M | (15.8M) | 30K | 68.59M | 63.86M |
| Gross Margin | 96.1% | -1200.9% | 100.0% | 76.9% | 75.8% |
| Research & Development | 20.27M | 18.38M | 20.27M | 19.58M | 13.18M |
| Selling, General & Admin | 4.69M | 18.66M | 47.28M | 0 | 230.12M |
| Operating Expenses | 24.75M | 19.71M | 67.55M | 71.68M | 243.3M |
| Depreciation & Amortization | 213K | 319K | 73K | 79K | 1.37M |
| EBITDA | (19.92M) | (34.36M) | (54.29M) | 8.37M | (167.41M) |
| EBITDA Margin | -361.9% | -2611.2% | -180973.3% | 9.4% | -198.6% |
| Operating Income | (19.45M) | (35.52M) | (67.52M) | (3.08M) | (179.45M) |
| Operating Margin | -353.3% | -2698.8% | -225066.7% | -3.5% | -212.9% |
| Interest Income | 800K | 0 | 0 | 0 | 10.67M |
| Interest Expense | 106K | 0 | 0 | 0 | 2.6M |
| Other Income / Expenses | (789K) | 834K | 13.16M | 11.37M | 8.07M |
| Income Before Tax | (20.24M) | (34.68M) | (54.37M) | 8.29M | (171.38M) |
| Pre-Tax Margin | -367.7% | -2635.4% | -181216.7% | 9.3% | -203.3% |
| Income Tax Expense | 0 | 0 | 0 | 288K | (80K) |
| Net Income | (20.24M) | (34.68M) | (54.37M) | 8M | (171.3M) |
| Net Margin | -367.7% | -2635.4% | -181216.7% | 9.0% | -203.3% |
| EPS (Basic) | (0.70) | (0.87) | (0.57) | 0.08 | (1.74) |
| EPS (Diluted) | (0.70) | (0.87) | (0.57) | 0.08 | (1.74) |
| Weighted Avg Shares | 28.87M | 39.96M | 95.22M | 96.94M | 98.57M |
| Weighted Avg Shares (Diluted) | 28.87M | 39.96M | 95.22M | 102.39M | 98.57M |
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.